BUZZ — Ultragenyx rises after FDA nod for rare disorder drug
* Shares of drugmaker Ultragenyx Pharmaceutical rise 1% to $14.65 premarket, after closing up 12.58% on Thursday * US Food and Drug Administration late on Thursday approved Ultragenyx's gene therapy, Fayuvi, as the first treatment for children with Sanfilippo syndrome Type A * Sanfilippo syndrome Type A is an inherited